Shermaine TilleyManaging Partner, CTI Life Sciences Fund
Since joining CTI Life Sciences Fund (CTI LSF) at its inception in 2006, Shermaine has played a critical role in each of the investments made by the Fund, but particularly by leading investments in Medicago – acquired by Mitsubishi Tanabe for $357 M in 2013 – as well as those in IMV (IMV: Nasdaq & TSX) and Zymeworks (ZYME: NYSE & TSX). She was also a board observer in Enobia that was acquired by Alexion in 2012 for $1.1B, assuming all milestones are received.
Prior to joining CTI LSF, Dr. Tilley was Senior VP at DRI Capital Inc. (formerly Drug Royalty Corporation), the world’s first private equity firm doing royalty transactions in the biotech/pharma space. Before DRI Capital Inc., Dr. Tilleyran and managed a research laboratory, holding faculty positions at the NYU School of Medicine and Public Health Research Institute (“PHRI”), NY, and on the PHRI Board of Directors. Concomitantly with her tenure at NYU School of Medicine and PHRI, she consulted for the NIH Small Business Innovation Research (“SBIR”) program in immunology and infectious disease for 10 years. Dr. Tilley holds a Ph.D. in biochemistry from the Johns Hopkins University School of Medicine, an MBA from the University of Toronto, and is a member of the CFA Society of Toronto. She currently sits on the boards of IMV, CellAegis Devices, Phemi, BIOTECanada and MaRS Innovation.